Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: A Bulgarian study

Journal of Medical Microbiology

Volumn 61, Issue 1, 2012, Pages 85-93

  Boyanova, Lyudmila ^a   Ilieva, Juliana ^a   Gergova, Galina ^a   Davidkov, Lubomir ^b   Spassova, Zoya ^c   Kamburov, Victor ^d   Katsarov, Nikolai ^b   Mitov, Ivan ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^c UNIVERSITY HOSPITAL ST IVAN RILSKI   (Bulgaria)

^d Pirogov Emergency Hospital   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TETRACYCLINE; YOGHURT;

ADULT; AGED; ANAMNESIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BIRTHPLACE; COFFEE; DIABETES MELLITUS; DIETARY INTAKE; EDUCATIONAL STATUS; FEMALE; GARLIC; HEALTH CARE PERSONNEL; HELICOBACTER PYLORI; HONEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAT; MIXED INFECTION; NONHUMAN; ONION; PRIORITY JOURNAL; QUESTIONNAIRE; RESIDENTIAL AREA; RESPIRATORY TRACT INFECTION; RISK FACTOR; SMOKING; TEA; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BULGARIA; CLARITHROMYCIN; COINFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HEALTH PERSONNEL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; QUESTIONNAIRES; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; SOCIOECONOMIC FACTORS; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 83755178141     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.035568-0     Document Type: Article

References (33)

1. Arfons, L., Ray, A. J. & Donskey, C. J. (2005). Clostridium difficile infection among health care workers receiving antibiotic therapy. Clin Infect Dis 40, 1384-1385.
2. Aupee, O., Almeras, D., Le Garlantezec, P. & Bohand, X. (2009). [Doxycycline]. Med Trop (Mars) 69, 556-558 (in French).
3. Boyanova, L. (2007). Detection of Helicobacter pylori infection in symptomatic Bulgarian adults. Clin Microbiol Infect 13, 908-914.
4. Boyanova, L. & Mitov, I. (2010). Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 8, 59-70.
5. Boyanova, L., Gergova, G., Nikolov, R., Davidkov, L., Kamburov, V., Jelev, C. & Mitov, I. (2008). Prevalence and evolution of Helicobacter pylori resistance to 6 antibacterial agents over 12 years and correlation between susceptibility testing methods. Diagn Microbiol Infect Dis 60, 409-415.
6. Boyanova, L., Ilieva, J., Gergova, G., Spassova, Z., Nikolov, R., Davidkov, L., Evstatiev, I., Kamburov, V., Katsarov, N. & Mitov, I. (2009). Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of Helicobacter pylori in Bulgaria. J Med Microbiol 58, 94-100.
7. Carothers, J. J., Bruce, M. G., Hennessy, T.W., Bensler, M., Morris, J.M., Reasonover, A. L., Hurlburt, D. A., Parkinson, A. J., Coleman, J. M. & McMahon, B. J. (2007). The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 44, e5-e8.
8. CLSI (2010). Performance Standards for Antimicrobial Susceptibility Testing, 20th Informational Supplement; Approved Standard. M100- S20. Wayne, PA: Clinical and Laboratory Standards Institute.
9. De Schryver, A., Cornelis, K., Van Winckel, M., Moens, G., Devlies, G., Derthoo, D. & van Sprundel, M. (2008). The occupational risk of Helicobacter pylori infection among workers in institutions for people with intellectual disability. Occup Environ Med 65, 587-591.
10. Demir, M., Gokturk, H. S., Ozturk, N. A., Arslan, H., Serin, E. & Yilmaz, U. (2009). Clarithromycin resistance and efficacy of clarithromycincontaining triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. South Med J 102, 1116-1120.
11. Francavilla, R., Lionetti, E., Castellaneta, S., Margiotta, M., Piscitelli, D., Lorenzo, L., Cavallo, L. & Ierardi, E. (2010). Clarithromycinresistant genotypes and eradication of Helicobacter pylori. J Pediatr 157, 228-232.
12. Graham, D. Y. & Shiotani, A. (2008). New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 5, 321-331.
13. Kist, M. & Glocker, E. (2004). ResiNet - a nationwide German sentinel study for surveillance and analysis of antimicrobial resistance in Helicobacter pylori. Eurosurveillance 8, 44-45.
14. Koivisto, T. T., Rautelin, H. I., Voutilainen, M. E., Niemelä, S. E., Heikkinen, M., Sipponen, P. I. & Fä rkkilä, M. A. (2004). Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. Aliment Pharmacol Ther 19, 1009-1017.
15. Kostamo, P., Veijola, L., Oksanen, A., Sarna, S. & Rautelin, H. (2011). Recent trends in primary antimicrobial resistance of Helicobacter pylori in Finland. Int J Antimicrob Agents 37, 22-25.
16. Lindberg, R. H., Björklund, K., Rendahl, P., Johansson, M. I., Tysklind, M. & Andersson, B. A. (2007). Environmental risk assessment of antibiotics in the Swedish environment with emphasis on sewage treatment plants. Water Res 41, 613-619.
17. McMahon, B. J., Hennessy, T. W., Bensler, J. M., Bruden, D. L., Parkinson, A. J., Morris, J. M., Reasonover, A. L., Hurlburt, D. A., Bruce, M. G. & other authors (2003). The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 139, 463-469.
18. Me ́ graud, F. (2004a). H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53, 1374-1384.
19. Mé graud, F. (2004b). Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 64, 1893-1904.
20. Me ́ graud, F. & Lehours, P. (2007). Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 20, 280-322.
21. Miendje Deyi, V. Y., Bontems, P., Vanderpas, J., De Koster, E., Ntounda, R., Van den Borre, C., Cadranel, S. & Burette, A. (2011). Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol 49, 2200-2209.
22. Nishizawa, T., Suzuki, H. & Hibi, T. (2009). Quinolone-based thirdline therapy for Helicobacter pylori eradication. J Clin Biochem Nutr 44, 119-124.
23. O'Connor, A., Taneike, I., Nami, A., Fitzgerald, N., Murphy, P., Ryan, B., O'Connor, H., Qasim, A., Breslin, N. & O'mora ́in, C. (2010). Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur J Gastroenterol Hepatol 22, 1123-1127.
24. Ojetti, V., Migneco, A., Silveri, N. G., Ghirlanda, G., Gasbarrini, G. & Gasbarrini, A. (2005). The role of H. pylori infection in diabetes. Curr Diabetes Rev 1, 343-347.
25. Ornelas, I. J., Galvan-Potrillo, M. & Lo ́ pez-Carrillo, L. (2007). Protective effect of yoghurt consumption on Helicobacter pylori seropositivity in a Mexican population. Public Health Nutr 10, 1283-1287.
26. Perna, F., Zullo, A., Ricci, C., Hassan, C., Morini, S. & Vaira, D. (2007). Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 39, 1001-1005.
27. Raikova, V. (2010). Microbiological studies on Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and genital mycoplasmas as causative agents of sexually transmitted diseases. PhD thesis, Medical University of Sofia, Sofia, Bulgaria.
28. Rimbara, E., Fischbach, L. A. & Graham, D. Y. (2011). Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 8, 79-88.
29. Schwarzer, A., Urruzuno, P., Iwan ́ czak, B., Marti ́nez-Go ́ mez, M. Z., Kalach, N., Roma-Giannikou, E., Liptay, S., Bontem, P., Buderus, S. & other authors (2011). New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain. J Pediatr Gastroenterol Nutr 52, 424-428.
30. Talebi Bezmin Abadi, A., Mobarez, A. M., Taghvaei, T. & Wolfram, L. (2010). Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran. Helicobacter 15, 505-509.
31. Taneike, I., Nami, A., O'Connor, A., Fitzgerald, N., Murphy, P., Qasim, A., O'Connor, H. & O'Morain, C. (2009). Analysis of drug resistance and virulence-factor genotype of Irish Helicobacter pylori strains: is there any relationship between resistance to metronidazole and cagA status? Aliment Pharmacol Ther 30, 784-790.
32. Wü ppenhorst, N., Lenze, F., Ross, M. & Kist, M. (2011). Isolation and eradication of a clinical isolate of Helicobacter pylori resistant to five antimicrobials in Germany. J Antimicrob Chemother 66, 222-223.
33. Zullo, A., Perna, F., Hassan, C., Ricci, C., Saracino, I., Morini, S. & Vaira, D. (2007). Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 25, 1429-1434.